Thus, pancreatic cancer is, in principle, an attractive tumour type to test mTOR inhibitors, and indeed, preclinical studies in established pancreatic cancer cell lines support this notion (Grewe et al, 1999; Agbunag and Bar-Sagi, 2004; Ito et al, 2006). This evidence concerns the gene MTOR and familial pancreatic carcinoma.